ARCH Venture Fund Discloses 16.2% Stake in Kardigan Post-IPO, Including Recent $20M Purchase
KARD sits 29% above its 52-week low of $20.07 on elevated volume (1.8× avg).
Summary
ARCH Venture Fund XIII, L.P. disclosed a 16.2% stake in Kardigan, Inc. post-IPO, including a recent $20 million purchase of shares at the IPO price, signaling strong institutional confidence.
Key Events · Ownership and Investor Activity · KARD
-
Major Stake Disclosure
ARCH Venture Fund XIII, L.P. and its affiliates disclosed a 16.2% beneficial ownership stake in Kardigan, Inc. following its recent IPO.
-
Post-IPO Share Purchase
The fund purchased 1,250,000 shares of common stock at the IPO price of $16.00 per share on June 22, 2026, totaling $20 million.
-
Significant Total Investment
The total investment by ARCH Venture Fund XIII in Kardigan, Inc. amounts to approximately $195 million.
-
Lock-Up Agreement in Place
The fund is subject to a standard 180-day lock-up period from June 17, 2026, restricting the sale of shares.
Analysis · KARD · Life Sciences
ARCH Venture Fund XIII, L.P., a prominent venture capital firm, has disclosed a substantial 16.2% ownership stake in Kardigan, Inc. following its recent IPO. This filing reveals that the fund, along with its affiliated investment committee members, made a significant purchase of 1.25 million shares at the IPO price of $16.00 on June 22, 2026, just days after the company's public debut. This direct investment, totaling $20 million, demonstrates strong conviction from a foundational investor, especially as Kardigan's stock has since traded significantly higher than the IPO price. The total investment by ARCH Venture Fund XIII in Kardigan now stands at approximately $195 million, underscoring deep institutional backing for the newly public life sciences company.
At the time of this filing, KARD was trading at $25.90 on NASDAQ in the Life Sciences sector. The 52-week trading range was $20.07 to $27.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.